Program Description & Educational Objectives
In this activity, experts in renal cell carcinoma discuss the most relevant and up-to-date information regarding current and emerging therapeutic options for advanced renal cell carcinoma.
Upon completion of this activity, participants should be better able to:
- Evaluate the clinical utility of prognostic markers to guide the therapeutic decision-making process in patients with renal cell carcinoma (RCC)
- Compare and contrast the mechanisms of action, efficacy, and adverse event profiles of established and emerging targeted therapies for advanced RCC
- Incorporate the most appropriate sequence of targeted therapies into individualized treatment plans for patients with advanced RCC based on tumor histology and patient prognosis
- Describe clinical scenarios that facilitate integration of emerging targeted therapies into the management of patients with advanced RCC
Target Audience
This activity has been designed to meet the educational needs of oncologists, urologists, and other clinicians involved in the management of patients with kidney cancer.
Requirements for Successful Completion
In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.
Media: Internet
Release and Expiration Dates: December 12, 2011 - December 11, 2012
Time to Complete: 30 minutes
Faculty & Disclosure / Conflict of Interest Policy
In accordance with ACCME requirements, the University of Florida College of Medicine has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.
Course Director and Interviewee
Robert J. Motzer, MD
Professor of Medicine
Weill Medical College of Cornell University
Attending Physician
Memorial Sloan-Kettering Cancer Center
New York, New York
Robert J. Motzer, MD,
has a financial interest/relationship or affiliation in the form of:
Consultant for Pfizer Inc.
Grant/Research Support from AVEO Pharmaceuticals, Inc.; Bristol-Myers Squibb; GlaxoSmithKline; Novartis AG; and Pfizer Inc.
Interviewee
Brian I. Rini, MD, FACP
Associate Professor of Medicine
Cleveland Clinic Foundation Lerner College of Medicine
Department of Solid Tumor Oncology
Cleveland Clinic Taussig Cancer Institute
Glickman Urological and Kidney Institute
Cleveland, Ohio
Brian I. Rini, MD, FACP,
has a financial interest/relationship or affiliation in the form of:
Consultant for AVEO Pharmaceuticals, Inc.; Genentech, Inc.; GlaxoSmithKline; and Pfizer Inc.
Grant/Research Support from Bristol-Myers Squibb; GlaxoSmithKline; immatics biotechnologies; and Pfizer Inc.
CME Reviewer
Li-Ming Su, MD
David A. Cofrin Professor of Urology
Associate Chairman of Clinical Affairs
Chief, Division of Robotic & Minimally Invasive Urologic Surgery
Department of Urology
University of Florida College of Medicine
Gainesville, Florida
Li-Ming Su, MD,
currently has no financial interests/relationships or affiliations in relation to this activity.
Content Director
Kathryn B. Charalambous, PhD
PVI, PeerView Institute for Medical Education
Kathryn B. Charalambous, PhD,
currently has no financial interests/relationships or affiliations in relation to this activity.
Sponsorship, Credit & Support
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the University of Florida College of Medicine and PVI, PeerView Institute for Medical Education. The University of Florida College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The University of Florida College of Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This CME activity is jointly sponsored by the University of Florida College of Medicine and PVI, PeerView Institute for Medical Education.
This activity is supported by an educational grant from 
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.
No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.
Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.
